Warning: Javascript must be enabled within your browser's settings for this site to function properly.

Your browser appears to be out of date, and is not supported by this site. For the best experience, we recommend that you upgrade to a more modern browser. You can find a list of modern browsers from www.browsehappy.com.

We use technical and analytics cookies data to ensure that we give you the best experience on our website. For more information visit our Privacy Page.

BWXT $   $  
As of . Minimum 20 minute delay.

News


BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology

16 November 2023

(OTTAWA, Ontario – November 16, 2023) – BWXT Medical Ltd. and Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) today announced that the companies have entered into an agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.


BWXT Medical and Laurentis Complete Key Tc-99m Generator Program Milestone

01 February 2023

(Ottawa, Ontario – February 1, 2023) – Life-saving Molybdenum-99 (Mo-99) isotopes can now be produced at Ontario Power Generation’s (OPG) Darlington Nuclear Generating Station, thanks to the installation and initial commissioning of an innovative isotope system by Laurentis Energy Partners and BWXT Medical Ltd. (NYSE: BWXT).


Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies

05 January 2023

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), today announced that the companies have entered into a preferred partner agreement for the supply of actinium-225.


BWXT Medical Names Andrea Greenberg as Vice President, Strategic Services

01 December 2022

BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT Medical Ltd. has appointed Andrea Greenberg as vice president, Strategic Services.